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The Birth of Clinical Organ Transplantation 
Thomas E Starzl, MD, PhD, FACS 
The task of describing the birth of organ transplantation 
was simplified by an historical consensus development 
conference convened on March 25-27, 1999 at the Uni-
versity of California, Los Angeles (UCLA). The purpose 
was to identifY the principal milestones leading to the 
clinical use of the various transplantation procedures. 
The II-member consensus panel included eight recipi-
ents of the Medawar Prize (the highest distinction of the 
Transplantation Society) and three Nobel Laureates 
(Figure O. 
Carl Groth of Stockholm, president-elect of the 
Transplantation Society, was invited to chair the delib-
erations and to prepare an executive summary of the 
group's conclusions. The summary, and personal remi-
niscences of the 11 individual participants, were pub-
lished in the July 2000 issue of the World Journal of 
Surgery. 1 The collection of articles was reprinted in 
monograph form for distribution to members of the 
Transplantation Society. 
Milestone status was granted only to contributions 
made at least a quarter of a century ago. By 1975, 32 
years had passed since convincing evidence was pro-
duced, first by Gibson and Medawar in a skin-grafted 
burn victim in Glasgow and then by Medawar in con-
trolled animal experiments, that rejection is a host versus 
graft (HVG) immune response. Within the next few years, 
it was demonstrated that the same principle applied to renal 
allografts in unmodified dogs (Figure 2B).4.5 
In addition, confirmatory observations were made in 
more than a dozen cases in which kidney allografts were 
transplanted to the anterior thigh6 or to the pelvis7-10 of 
unmodified human recipients. These cases included the 
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first reported live organ donation;? the mother's kidney 
functioned for 3 weeks in her nonimmunosuppressed 
son before undergoing irreversible rejection. 
It is noteworthy that, as early as 1951, the French 
surgeons Kuss and coworkers,S Dubost and associates,9 
and Servelle and colleagues,lo had developed for human 
use the extraperitoneal pelvic kidney transplant proce-
dure that soon would be used by Murray and col-
leagues 11 for the historic identical twin and fraternal twin 
transplantations12 of 1954 and 1959, respectively. Proce-
dures for transplantation of the other vital organs had been 
developed in surgical laboratories by the late 1960s. By the 
end of the decade, therapeutic regimens were available with 
which successful clinical transplantation of five kinds of 
organ allografts, as well as allogeneic bone marrow cells, 
were accomplished (Table 1).12-17 
In my individual contribution to the UCLA confer-
ence,18 I pointed out that almost all of the clinical trans-
plantation milestones could be traced to two seminal 
discoveries that were turning points from which diver-
gent management strategies evolved; one leading to 
bone marrow transplantation and the other to organ 
transplantation. The first discovery, made in the exper-
imentallaboratory and eventually applied in the clinic, 
was that acquired tolerance to allografts could be in-
duced. The second discovery, that organs could induce 
tolerance to themselves (ie, were inherently tolerogenic), 
was made by clinical surgeons and taken to the labora-
tory in search of an explanation. 
When no explanation for the organ tolerogenicity could 
be found, the engraftment of organs was incorrectlyattrib-
uted by consensus to different mechanisms than those of 
acquired tolerance. The error did not prevent the develop-
ment of organ transplantation to a high level of efficacy. But 
it deprived transplantation immunology of an intelligible 
context for nearly three decades. 
TURNING POINT 1: ACQUIRED TOLERANCE 
The demonstration that tolerance to allogeneic tissue 
could be acquired is dated precisely to a four-page exper-
imental article by the English team of Billingham, Brent, 
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Figure 1. Participants at the UCLA historical concensus development conference on transplantation milestones. Front row (left to right): 
Robert A Good, Norman E Shumway.* E Donna" Thomas,t Joseph E Murray,t Jean B Dausset,*t Jon J Van Rood;* Back row (left to right): 
Leslie B Brent, * Roy Y Caine, * Paull Terasaki, * Robert S Schwartz, * Carl G Groth, Thomas E Starzl. * *Recipient of Medawar Prize. tRecipient 
of Nobel Prize. (By permission of the World Joumal of Surgery: 2000;24:755-843.) 
and Medawar in the October 3, 1953, issue of the jour-
nal Nature. 19 The tolerance was strongly associated with 
donor leukocyte chimerism. 19.20 
The animal tolerance models 
In their initial experiments, Billingham, Brent, and Me-
dawar induced tolerance to subsequently transplanted 
skin allografts by first engrafting self-renewing donor 
strain spleen cells into gestational and neonatal mice 
before the recipient animal's immune system was devel-
oped enough to reject the foreign leukocytes. '9 Sixteen 
months later, Main and Prehn21 at the National Cancer 
Institute (Bethesda, MO) extended these findings to 
adult mice that were rendered comparably immune-
defenseless by supralethal total body irradiation (TBl) 
and then rescued by an infusion of donor bone marrow 
cells. In both the neonatal and irradiation mouse mod-
els, the acquired tolerance was limited to skin allografts 
from the leukocyte donor strain (donor-specific 
nonreactivity). 
Clinical bone marrow transplantation 
The mouse neonatal tolerance '9.2o and irradiation toler-
ance models21 were the direct forerunners of bone mar-
row transplantation to patients with immune deficiency 
diseases ,s .22 and to cytoablated recipients made immune 
deficient by TBI,2,·24 respectively. As in the mice, the 
limiting factor in humans under both circumstances was 
the need for a close tissue match. Otherwise, lethal graft 
versus host disease (GVHO), viewed simplistically as a 
one-way immune reaction opposite to the HVG reac-
tion of tissue and organ rejection (Figure 2A), was a 
nearly inevitable consequence of engraftment. ".22-21 Be-
cause human leukocyte antigen (HLA) typing was not 
available until 1968, unequivocally successful clinical 
bone marrow transplantation was not accomplished un-
til then. 
Six of the 11 pioneers at the UCLA conference had 
been prime contributors to the ascension from mouse to 
man of bone marrow transplantation: Leslie Brent, Rob-
ert Good (who performed the first unquestionably suc-
-
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Figure 2. Misleading historical context of transplantation immunol-
ogy, defined by unidirectional cell-mediated immune reactions. (B) A 
host-versus-graft (HVG) response against a tissue or organ (here a 
kidney). (A) A mirror image version after bone marrow transplanta-
tion in which a graft-versus-host (GVH) response is mounted by 
donor hematolymphopoietic (eg, bone marrow) cells against a host 
made defenseless by functional immaturity of its immune system 
(the neonatal tolerance model), cytoablation (eg, total body irradia-
tion), or breeding (the parent to defenseless offspring F1 hybrid 
models). 
cessful human bone marrow transplantation), E Don-
nall Thomas (bone marrow transplant pioneer and 1990 
Nobel Laureate), and three of the fathers of tissue 
matching (Paul Terasaki, Jon van Rood, and the 1980 
Nobel Laureate, Jean Dausset). 
TURNING POINT 2: ORGAN TOLEROGENICITY 
The principal contributions of the five other panel 
members at the UCLA conference had been to organ 
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Table :1.. Historical Firsts: Prolonged Patient and Allograft 
Survival 
Date of 
Organ City TX Reference 
Kidney Boston 1124/59 12 
Liver Denver 7/23/67 13 
Heart CapeTown 1/2/68 14 
Bone marrow Minneapolis 8/24/68 15 
Lung" Ghent 11/14/68 16 
Pancreast Minneapolis 6/3/69 17 
'Patient died after 10 monrhs; all others in table lived> one year with func-
tioning graft. The first> one year survival of isolated lung recipients was not 
reported until 1987. 
tKidney and pancreas allografts from same donor to uremic patient. 
TX, transplantation. 
transplantation (Figure 1). Four of the five were sur-
geons: Roy Calne, Norm Shumway (pioneer of thoracic 
organ transplantation), Joe Murray, and myself. The 
fifth was the hematologist, Bob Schwanz, whose inves-
tigations in 1958-1960 of 6-mercaptopurine (6MP)25.26 
made him the father of chemical immunosuppression 
(see later). 
In contrast to the prompt acknowledgment that do-
nor leukocyte chimerism-associated acquired tolerance 
was the touchstone of bone marrow transplantation, the 
concept of allograft tolerogenicity upon which the de-
velopment of organ transplantation depended27 was dis-
counted by leading authorities.28,29 In retrospect, how-
ever, the tolerogenicity of kidneys was self-evident from 
the time of the very first successful renal transplanta-
tion.30 Moreover, this property was exploited unknow-
ingly or deliberately in the evolution of renal transplan-
tation and for the subsequent transplantation of all the 
other organs, using a variety of antirejection modalities. 
Using total body Irradiation 
Resistance to the idea that organs are tolerogenic can be 
traced to the demonstration between 1959-1963 that 
kidney allografts could be successfully transplanted in 
the ostensible absence of donor leukocyte chimerism. 
This was contrary to the expectation that the immune 
barrier would have to be surmounted by simulating the 
mouse irradiation tolerance model. The anticipated 
strategy consisted of recipient total body irradiation 
(TBI) and infusion of donor bone marrow cells with 
establishment of a donor leukocyte chimerism-
associated tolerant state before or at the time of organ 
implantation. 
When such protocols were tested over a period of 
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Table 2. Kidney Transplantation with One Year Survival as of April, 1963 
Survival 
Patient No. City * Date Donor (molt 
1 Boston 12.30 1-24-59 Frat twin 246 (Died) 
2 Paris'6.3? 6-29-59 Frat twin 312 (Died) 
3 ParisJ " 6-22-60 Unrelatedl'·§ 18 (Died) 
4 Paris" 12-19-60 Motherl' 12 (Died) 
5 Paris'S 12-3-61 Unrelatedfs ---- -- 18 (Died) 
6 ParisJ7 2-12-62 Cousinl' 180 (Retx) 
................................................................................................................................................................... 
7 BostonY> 4-5-62 Unrelated 17 (Died) 
'Boston: JE Murray (patients 1 and 7); Paris: J Hamburger (patients 2, 4 and 6); R Kuss: (patients 3 and 5). 
tThe kidneys in patients 1 and 2 functioned for 20.5 and 26 years, respectively, until death from nonrenal causes. When the cousin kidney in patient 6 failed after 
15 years, retransplantation was done successfully, and at jast report the patient had become a member of the French parliament. Patient 7 rejected his graft after 
17 months and died after rerurn to dialysis. 
*Adjunct steroid therapy. 
§ Adjunct 6-mercaptopurine. 
(Died), with functioning graft or within a short time after graft failed; Frat, fraternal; (Rerx), retransplantation. 
several years in the canine kidney transplant model, 
however, they yielded only a single animal with survival 
of73 days.31 Death of this dog was caused by pneumonia 
rather than kidney rejection. Because the donor and re-
cipient were from the same purebred beagle colony, the 
most logical explanation for the absence of allograft re-
jection was that the animals had a fortuitously good 
tissue match. 
Exhaustive efforts to use the bone marrow-kidney 
transplant strategy in irradiated mongrel dogs by David 
Hume at the Medical College of Virginia resulted in no 
survival prolongation.32 Hume also extensively evalu-
ated the possibility of treating the recipient with TBI 
only (without bone marrow infusion). Although it was 
known from military-related research that TBI was im-
munosuppressive per se, irradiation by itself was uni-
formly unsuccessful in the canine kidney transplant 
model. 
The bleak experimental results were all the more frus-
trating because the potential value of organ transplanta-
tion had been obvious in a series of human identical twin 
(monozygotic) kidney transplantations in Boston by the 
furure Nobel laureate, Joseph Murray.Il·33.34 Undoubt-
edly inspired by these results in the absence of an im-
mune barrier, Murray and colleagues proceeded with a 
non-identical (fraternal or dizygotic) twin kidney trans-
plantation on January 24, 1959, using 450R TBI with-
out donor bone marrow infusion. 12.30 
The renal allograft functioned until the fraternal twin 
recipient's death from cardiovascular disease OM~ years 
later. It was the first successful transplantation ~ of an 
organ allograft in any species, and in my opinion, the 
single most important clinical case in the history of 
transplantation. But it was the only example of recipient 
survival exceeding 1 month in 12 attempts to use TBI at 
the Peter Bent Brigham Hospital.35 
The dream of organ transplantation was kept alive 
during the next four years by the independent French 
teams ofJean Hamburger6•37 and Rene KUSS38 who pro-
duced five further successes. By April 1963, there had 
been six I-year survivors post-kidney transplantation in 
the world after sublethal recipient irradiation, all with-
out adjunct donor bone marrow infusion (Table 2, 
above dotted line).12.30.36-38 Two of the six donors were 
fraternal twins, two others were a mother and a cousin, 
and most importantly, two had no genetic relationship 
to the recipients (Table 2). 
Using pharmacologic immunosuppression 
In the meanwhile, drug therapy was on the horizon. The 
two irradiated recipients of non-related kidneys in Table 
2 (patients 3 and 5) had been treated by KUss with de-
layed doses of 6MP and cortisone. In addition, two of 
Hamburger's patients (Table 2, patients 4 and 6) prob-
ably were given short courses of steroid therapy. Finally, 
patient 7 (Table 2, below the dorted line) had reached 
the I-year post-transplantation milestone under drug 
treatment only (see beloW).39 
Adrenal cortical steroids 
It had been established in the early 1950s by Billingham, 
Krohn, and Medawar,40 Morgan,41 and others42-45 that 
cortisone modestly but significantly delayed the rejec-
tion of skin allografts in mice, guinea pigs, and rabbits. 
The prolongation was so limited that the drug was 
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viewed as a minor immunosuppressant. Nevertheless, a 
neglected report by Cannon and Longmire46 contained a 
hint of the true value of steroid therapy. 
Cannon and Longmire demonstrated that a 6% inci-
dence of spontaneous permanent tolerance to skin allo-
grafts in newly hatched chicks (an important finding per 
se) rose to more than 20% with administration of a short 
course of cortisone. In their prescient discussion, the 
authors' noted that the steroid effect, " ... appeared to 
maintain itself after the drug was discontinued. This 
phenomenon is one which up to the present time has not 
been found in homograft experiments on mammals and 
humans".46 
Like natural cortisone, the far more potent synthetic 
steroid, prednisone, had very little efficacy when used 
alone in adult animal recipients of allografts. In an iso-
lated exception, however, Zukoski and associates47 re-
ported the 649-day survival of a mongrel kidney recipi-
ent (1 out of 15 experiments) that had been treated with 
prednisone for 420 days. Renal function had been stable 
throughout the subsequent drug-free interval of 229 
days. As in the Cannon-Longmire chick experiments, 
the effect of the steroid therapy appeared to have far 
outlasted the duration of drug treatment. 
Finally, an important clinical observation was made in 
Los Angeles, where a kidney transplantation program 
had been launched by Willard Goodwin in 1960, but 
closed in. 1961 after the deaths of six consecutive reci p-
ients. In the third case of this UCLA series, Goodwin 
transiently reversed several rejections with prednisone 
during the 144-day survival of a live donor kidney recip-
ient who had been conditioned with myelotoxic doses of 
cytoxan (cyclophosphamide) and methotrexate (ameth-
opterin) rather than with TBI. Unfortunately, the case 
was not reported until 1963.48 
6-mercaptopurine (6-MP) and azathioprine 
The era of chemical immunosuppression began with the 
demonstration in 1959 by Schwartz and Dameshek26 
that 6MP prolonged skin allograft survival in rabbits, an 
observation that was promptly confirmed by Meeker 
and colleagues.49 Preclinical studies in the canine kidney 
transplant model were carried our by Zukoski, Lee, and 
Hume in Richmond, VA,50 and independently by Roy 
Calne in London. 51 
Before moving from London to Boston in July 1960 
to continue his canine studies with Murray, CaIne (see 
Figure 1) used 6MP as the baseline immunosuppressant 
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for three unsuccessful human kidney transplantations 
on the service ofJohn Hopewell at the Royal Free Hos-
pital (London).52 Shortly after arriving at the Peter Bent 
Brigham Hospital, where Murray already had unsuccess-
fully treated a kidney recipient with 6MP in April 
1960,35.39 Calne and Murray began studies of the 6-MP 
analogue, azathioprine. 53,54 
Twenty-one months later, on April 5, 1962, Murray 
transplanted a kidney from a nonrelated donor to the 
recipient shown below the dotted line in Table 2, who 
was treated from the time of operation with azathio-
prine, without conditioning by TBI,39 Except for Good-
win's patient who had lived for 144 days under treatment 
with cyclophosphamide, methotrexate, and prednisone 
(see earlier},48 this was the first example in the world of 
extended survival of a human kidney recipient using 
chemical immunosuppression only. The renal allograft 
in Murray's case was failing in April, .1963 (blood urea 
nitrogen 100 mg/deciliter),39 but the organ was destined 
to keep this seventh one-year kidney transplant survivor 
dialysis-free for another five months (total 17 months). 
The magnitude of the sea change that would be 
caused by 6MP and azathioprine was not immediately 
apparent. Less than 5% of the canine kidney recipients 
treated with the new drugs survived for as long as 100 
days.28,35,53.54 Moreover, the encouraging result in Mur-
ray's April 5, 1962, case (Table 2) was the only example 
of survival exceeding 6 months among the first 13 kid-
ney recipients treated by Murray or Calne with either 
6MP or azathioprine, including Calne's 3 English pa-
tients52 and the first 10 treated in Boston.35.39 
Similar tantalizing but disappointing results were ob-
tained in 10 cases compiled between July, 1962, and the 
first week of February, 1963, by Hume and coworkers55 
in Richmond (n = 4) and by Woodruff and colleagues56 
in Edinburgh (n = 6). One patient from each series sur-
vived for one year. Azathioprine was combined with TBI 
in Hume's four recipients. Except for the reversal of re-
jection with prednisone in the last of Woodruff's recip-
ients, the role, if any, of steroid therapy in these non-
standardized multimodality protocols could not be 
distinguished from that of the other treatments (TBI, 
actinomycin C, guanethidine, graft irradiation). 
In March, 1963, Hume added patients 5 and 6 to his 
Virginia series, after abandoning TBI conditioning. Us-
ing the double drug Colorado protocol,57 the first of 
Hume's additional patients survived for more than 25 
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Table 3. Empirical Therapeutic Algorithm for Immunosuppression 
Ingredients of treatment strategy 
Baseline therapy 
Principal drugs used for baseline 
Immunosuppresslon* 
Azathioprine 
Cyclophosphamide 
Secondary adjustments of prednisone dose; initiation of antilymphoid agents 
or other adjunct drugs Cyclosporine 
Tacrolimus 
Case to case trial (and potential error) of drug weaning Mycophenolate moferil 
Rapamycin 
• Alone or with prophylactic prednisone or anrilyrnphoid antibody preparations (eg. ALG) or both. The antibody preparations were also used in "rescue" protocols 
(ie, instead of prednisone or ocher secondary agents). 
years after receipt of a sibling kidney on March 18, 
1963.58 
The azathioprine-prednisone cocktail 
The results of experimental studies in Colorado of aza-
thioprine in the canine kidney transplant model were no 
different than those in the Boston, Richmond, and Min-
neapolis surgical laboratories, with one important ex-
ception. Rather than being inexorable, kidney rejection 
in the azathioprine-treated dogs was readily reversed 
with a short course of prednisone.59 This finding, which 
had not been evident in the other experimental stud-
ies,53.54 was a key factor in the decision to begin the 
Denver clinical kidney transplant program in 1962. 
Now, there were three such centers in the United States: 
one each at Harvard, the Medical College of Virginia 
(also opened in 1962), and the University of Colorado. 
Goodwin's UClA program, which had closed in 1961, 
would not resume activities until well into 1963.60 
The management principles 
Eight of the first 10 recipients in the Colorado series had 
prolonged survival.27 Four of the transplanted kidneys 
functioned for more than 25 years, and 2 still function 
today after 38 years in the longest-surviving renal allo-
graft recipients in the world. "The Reversal of Rejection 
in Human Renal Allografts ... " described in the first 
part of the title of the 1963 reporcl7 had been presaged 
by the dog studies. 
In contrast, the crucial observation of" ... the Sub-
sequent Development of Homograft Tolerance" capsu-
lized in the second half of the tirle27 far exceeded expec-
tations. But the apparent induction of tolerance was 
inexplicable. Like the seven kidney recipients in Table 2 
who had survived at least 1 year after transplantation, 
none of our patients had been given an adjunct infusion 
of donor bone marrow cells. By inference, they did not 
have the donor leukocyte chimerism that was (and is) 
strongly associated with Medawarian (ie, neonatal) 
tolerance. 
Although the reason for engraftment in these cases 
was enigmatic, the experience allowed the formulation 
of a highly practical treatment algorithm. The algorithm 
(Table 3) consisted of recognition of kidney rejection 
patterns, a measured therapeutic response (usually with 
steroids), and subsequent dose weaning to the lowest 
maintenance levels consistent with stable graft function. 
Serial testing of the recipient's serum creatinine, creati-
nine clearance, blood urea nitrogen (BUN), or other 
functions was the most practical way to monitor HVG 
activity. Even when renal dysfunction was not detected, 
the development and regression of subclinical rejection 
in controlled animal experiments invariably could be 
demonstrated in serial biopsies of the allograft. 
The drug-free kidney recipient 
An umbrella of prophylactic immunosuppression is re-
quired for the tolerogenicity of kidney allografts to be 
manifest in humans and in most other large animals 
species, including dogs. In a small percentage of kidney 
transplant experiments in mongrel dogs, however, it was 
learned in 1962-1963 that a short course of azathio-
prine could be succeeded by drug-free tolerance to the 
allograft for long periods, or for the life of the 
animal. 28•61 -63 Similar independence from immunosup-
pression has been observed after human renal transplan-
tation, usually in recipients oflive donor related kidneys. 
Of our first 46 recipients of consanguineous kidneys 
treated at the University of Colorado before March, 
1964, 10 still have function of their original kidney al-
lografts after 36t-38 post-transplant years; 5 of the 10 
have been drug free for 7, 7, 19,33, and 34 years. 64 
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EXTRARENAL ORGAN TRANSPLANTATION 
As was anticipated/l .6s the treatment algorithm devel-
oped with kidney transplantation was generalizable, no 
matter what the cellular or molecular target of various 
immunosuppressants (Table 3) or what the organ. In the 
development of the organ-defined branches of clinical 
transplantation, guidelines and concepts developed with 
one kind of organ were applicable to all. But there were 
quantitative differences with the various allografts.66 For 
example, it was shown between 1963-1966 that 
immunosuppression-independence after organ trans-
plantation in mongrel dog experiments evolved under a 
4-month course of azathioprine67.68 or after a few injec-
tions of antilymphocyte serum (ALS) or antilymphocyte 
globulin (ALG)68 far more commonly in liver recipients 
than in kidney recipients. 
It was subsequently shown that lifetime tolerance to 
orthotopic liver allografts evolves without any treatment 
in 15% to 20% of randomly matched outbred pigs,69-n 
invariably in selected strain combinations of rats, 73.74 and 
in the vast majority of mouse strain combinations.75 
Heart75.76 and kidney allografts77 can also induce spon-
taneous tolerance in experimental rodent models, but 
with far fewer strain combinations. Accordingly, it has 
not been surprising that drug freedom 5 to 10 years after 
transplantation in humans has been achieved more fre-
quently by liver64.78-Bo than by kidn~·Bl or heart 
recipients. 
Despite the clear demonstration in experimental 
models of the relative immunologic privilege of the liver, 
our first five attempts at hepatic replacement between 
March 1, and October 4, 1963, resulted in recipient 
death after 0-23 days.82.B3 Single attempts also were un-
successful in Boston (September, 1963)84 and Paris Qan-
uary, 1964).85 Our failed trial in Colorado was reported 
in Surgery Gynecology and Obstetrics,82 2 months after 
publication in the same journal of our successful kidney 
experience,27 and it was presented at the April, 1964, 
annual meeting of the American Surgical Association. 83 
The kidney transplant programs burgeoned in Colo-
rado and elsewhere, while liver transplantation was sent 
back to the surgical research laboratories. Even before 
the availability of any kind of immunosuppression, chal-
lenges had been generated by the surgical difficulty, an-
atomic uniqueness, and physiologic complexity of re-
moval and replacement of the liver in the dog model. 
These challenges generated opportunities for broadly 
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ap~licable advances i.n surgical tech?ique, orffan preser-
vatlon, and metabollsm.83.86-93 DUrIng the 32 year self-
imposed moratorium on further clinical trials, experi-
mental liver transplantation became an even more fertile 
area for generic advances. 
For example, the decision in 1963 not to make further 
attempts at liver transplantation without better immu-
nosuppression resulted in purification, testing in dogs, 
and eventual clinical introduction of antilymphocyte 
globulin (ALG)94 for use in combination with azathio-
prine and prednisone.95 After it was shown in human 
kidney recipients that the addition of ALG to azathio-
prine and prednisone improved treatment efficacy, liver 
transplantation was accomplished with the same triple 
drug regimen on July 23, 1967. 13 
Trials with other extrarenal organs using the same 
treatment strategies were undertaken in the succeeding 
23 months. These resulted in the first successful clinical 
transplantation of the heatt,14 lung,16 and pancreas I? 
(Table 1). The world's longest-surviving recipient of an 
extrarenal organ is a 34-year-old woman whose liver re-
placement for biliary atresia was carried out more than 
31 years ago (Figure 3). 
Over the years, graft and patient survival of all trans-
planted organs, but most dramatically the liver (Figure 
4), improved in three distinct steps under azathioprine-
based, cyclosporine-based, and tacrolimus-based treat-
ment. When tacrolimus became available, intestinal and 
multivisceral transplantation procedures that had been 
first described at the American Surgical Association in 
195996 and at the Surgical Forum of the American Col-
lege of Surgeons in 196097 graduated from "experimen-
tal" status98-100 to a bona fide place in the treatment 
armamentarium of the 21 S{ century. 101-104 
A 30-YEAR TREK IN THE WILDERNESS 
What actually was being achieved? Because organ en-
graftment had been accomplished without cotransplan-
tation of bone marrow cells, it was concluded by 1963 
that donor leukocyte chimerism, the sine qua non of the 
experimental tolerance models and of successful bone 
marrow transplantation, was not associated with organ 
engraftment. The equally erroneous corollary was that 
organ engraftment occurred by immunologic mecha-
nisms other than those of the acquired tolerance models 
and of clinical bone marrow transplantation. This view 
was not challenged for 30 years, in part because of the 
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Figure 3. Photograph at Three Rivers Stadium in Pittsburgh of a 
woman who underwent liver replacement for biliary atresia 31 years 
ago. The native liver contained an incidental hepatoma. She and her 
husband are beneath the statue of Roberto Clemente, the Hall of 
Fame Pittsburgh Pirate right fielder. 
striking clinical differences between organ and bone 
marrow transplantation (Figure 5). 
Derivative errors stockpiled. For example, the "pas-
senger leukocytes" of bone marrow origin, depicted in 
Figure 6 as a bone silhouette within a kidney, were 
known to be the most immunogenic component of pa-
renchymal organs. I ·"·,U8 It was recognized in 1969 that 
most of these donor leukocytes were replaced by recipi-
ent leukocytes of the same lineages in successfully en-
grafted human livers, 1<19.110 a change subsequently dem-
onstrated in intestinal, 111.lll kidney'I.l,'14 (Figure 6), and 
all other org:m allografts.-" The chimerism-exclusionary 
explanation of organ engraftmem required the assump-
tion that these donor leukocytes had been selectively 
destroyed by the host immune system, either in situ'I5·116 
or after their migration into the recipient, 116·118 with the 
selective preservation of the organ's specialized paren-
chymal cells. 
In 1992, we asked a question that had not been re-
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Figure 4. The three eras of orthotopic liver transplantation at the 
Universities of Colorado (1963-1980) and Pittsburgh (1981-1993), 
defined by azathioprine (AZAr, cyclosporine (CYA)-, and tacrolimus 
(TAC)-based immune suppression. The same stepwise improvement 
was seen with all organs. Top family of curves: Patient survival. 
Bottom family: Graft survival. Patient sUl'Vival was about 10% higher 
than graft survival in both the cyclosporine (1980-1989) and ta-
crolimus eras (1989-1993) because of effective retransplantation. 
an option that did not exist previously in the azathioprine prime era. 
motely broached in the literature of the previous three 
decades. Could these donor passenger leukocytes, in-
cluding self-renewing hematolymphopoietic precursor' 
and stem cells, have migrated into the recipient as de-
picted in the body silhouette of Figure 6? If so, organ 
transplantation involved the systematic but unwitting 
infusion of donor hematolymphopoietic cells, in essence 
comparable to a donor bone marrow cell infusion. The 
possibility existed that the unrecognized production of 
donor leukocyte chimerism was, in fact, the reason why 
organ transplantation had been feasible. 
As the first step in testing the hypothesis, blood sam-
ples and biopsies were obtained from multiple host sites 
as well as the allografts in 30 patients who had borne 
kidney and liver allografts (Figure 7) for up to three 
decades. The specimens were analyzed for the presence 
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(Madawar) 
Rgure 5. The developmental tree of bone marrow (right) and whole 
organ transplantation (left) after it was demonstrated by Gibson and 
Medawar during World War II that rejection is an immunologic re-
sponse. GVHD: graft versus host disease. (By permission of Starzl 
TE: J Am Coli Surg 1995;180:332-336.) 
of donor leukocytes and donor DNA, using sensitive 
immunocytochemical and polymerase chain-reaction 
techniques. All 30 patients were shown to have low-level 
multilineage donor leukocyte chimerism (Figure 
6).78.119-122 
AN EPIPHANY 
The mystery of organ engraftment was solved. A satis-
factory clinical result after organ transplantation repre-
sented a stand-off between multilineage immunocyte 
populations of David (ie, donor) and Goliath (recipient) 
size proportions (Figure 8B), each of which induced tol-
erance of the other. Moreover, the historical view of an 
organ allograft as a defenseless island in a hostile sea (see 
Figure 2, bottom) had been a misleading over-
simplification. The clinically obvious response after or-
gan transplantation usually was HVG, while the GVH 
reaction usually was "invisible" (ie, subclinical). Stability 
of the equilibrium between the coexisting donor and 
recipient immune competent cells usually, but not al-
ways, required continued immunosuppression in hu-
man organ recipients. 
Conversely, the previous definition of an idealized 
result following bone marrow transplantation as total 
replacement of the host immune apparatus (Figure 2, 
top) was equally incorrect. Instead, successful bone mar-
row transplantation was a mirror image version of organ 
Starzl 
I 
• 
t 
• • I 
Birth of Clinical Organ Transplantation 
Nonlymphoid Tissue 
Localization 
3 
-months 
Lymphoid Tissue 
Localization 
439 
Rgure 6. Replacement by recipient cells of most of the highly 
immunogenic donor ·passenger" leukocytes of bone marrow origin 
(bone silhouette in the kidney, left) that occurs within three months 
after successful transplantation of all human organ allografts. Al-
though the disappearance of these donor cells was once explained 
by their selective destruction by the host immune system with 
selective sparing of the allograft's specialized parenchymal cells, 
the self-renewing multilineage donor cells had migrated into the 
recipient tissues (body silhouette at right). 
'* Heart .. ;;~I--K~-•• - ••• "e 
* Bone marrow ·.'.r-·+'.':Jfl 
Rgure 7. Host sites sampled in studies in 1992 of the longest-
surviving kidney and liver recipients in the world. Donor leukocyte 
chimerism was looked for in host blood, skin, and lymph nodes as 
well as the allograft (here liver) of all patients. In selected recipients, 
biopsies also were taken from the heart, intestine, other organs, or 
bone marrow. The concepts depicted in Figures 6 and 8-11 were 
deduced from these findings and confirmed in a series of controlled 
animal experiments. 
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FIgure 8. Definition of allograft acceptance in terms of double and 
mutually canceling immune reactions. Although the dominant reac· 
tion is usually host-versus-graft (HVG) after organ transplantation 
(bottom), and most commonly graft·versus-host (GVH) after bone 
marrow transplantation (top). The effective opposition to and mod· 
ulation of the stronger responses by the minority cell population is 
the key to engraftment after both kinds of transplantation. (By 
permission of the authors and the Journal of the American Medical 
Association, 1995;273:876-879.) 
transplantation with reversal of the size proportions of 
the donor and recipient immunocyte populations (Fig-
ure 8A).122,123 This view was supported by the discovery 
that residual host leukocytes invariably could be found 
in bone marrow recipients who previously had been 
thought to have complete donor leukocyte chimer-
ism. 124,125 
In the new paradigm that has been confirmed and 
extended with a series of controlled experimental 
studies/5,126-137 treatment failure after either bone mar-
row or organ transplantation was defined as the acute or 
chronic ascendancy of one or the other response arms 
J Am Coli Surg 
(Figure 9), or as a simultaneous perpetuation of both 
destructive immune reactions. To be successful, organ 
and bone marrow transplantation required the establish-
ment and maintenance of variable levels of mutual tol-
erance, the completeness of which determined the need 
or lack thereof for maintenance immunosuppression . 
Tolerance induction began with and depended on mi-
gration of donor leukocytes to organized lymphoid col-
lections and a simultaneous reverse traffic of host cells. 
The seminal mechanism of the mutual tolerance, was 
proposed to be induction of " ... [widespread] re-
sponses of co-existing donor and recipient immune cells, 
each to the other, causing reciprocal clonal expansion, 
followed by peripheral clonal deletion" .78.119 Since its 
publication in 1992, this hypothesis has been tested and 
verified in several experimental models. 130,132.138,139 
In addition to accounting for the characteristic cycle 
of immunologic crisis and resolution that occurs in the 
first 1-4 weeks after both organ and bone marrow trans-
plantation (Figure 9), the mutual modulation of the two 
immune responses explained the poor predictive value of 
HLA matching for organ transplantation. With each 
greater degree of incompatibility, both HVG and GVH 
responses were progressively ratcheted up, resulting in a 
sliding scale nullification (Figure 10). With the severe 
weakening of the host response arm in the immunode-
ficient or cytoablated bone marrow recipient, the hazard 
of GVHD was directly proportional to the tissue mis-
match (Figure 11). 
It also was apparent why the liver with its huge load of 
leukocytes was the most tolerogenic organ, but was 
rarely responsible for GVHD, providing the recipient 
was not immunocompromised in advance. 140 Moreover, 
the fear of causing GVHD that had forestalled clinical 
efforts to transplant the leukocyte-rich bowel and had 
discouraged strategies of organ and bone marrow co-
transplantation since the late 1950s (see earlier) was put 
to rest. Both intestinal transplantationl0l.104 and adjunct 
donor bone marrow infusion in immunologically intact 
recipientsJ41 ,142 were safe. In fact, intestinal transplanta-
tion alone or as part of a multivisceral graft has fre-
quently been carried out in combination with bone mar-
row cell infusion.l02.103 
The implications of this paradigm are not limited to 
transplantation. Throughout the quarter century pre-
ceding 1975, the field of immunology was preoccupied 
with studies of tumor and allograft rejection, reflected by 
the words major histocompatibility complex (MHC) to 
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Figure 9. Contemporaneous host-versus-graft (HVG) and graft-versus-host (GVH) reactions after 
transplantation. Treatment failure is defined as the inability to control one of the reactions. or 
sometimes both. Acute reciprocal clonal exhaustion is maintained after successful transplan-
tation by chimerism-dependent low-grade stimulation of both leukocyte populations that may 
wax and wane. (By permission of the New England Journal of Medicine 1998;339:1905-1913.) 
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Figure 10. The nullification effect of simultaneous host-versus-graft 
(HVG) and graft-versus-host (GVH) reactions when organs are trans-
planted to recipients whose immune system has not been cytoab-
lated. This is the explanation for the poor correlation of HLA match-
ing with outcome after organ transplantation (see text). 
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Figure 11. Because recipient immune reactivity is maximally de-
functionalized at the time of bone marrow cell transplantation, the 
nullification of the host-versus-graft (HVG) and graft-versus-host 
(GVH) reactions shown in the top and third from the top balance bars 
(and also in Figure 10) is rendered largely inoperative. The GVHD 
caused by the unopposed donor leukocyte population is avoidable 
or manageable only if there is a good donor-recipient HLA match 
(second crossbar from top). With a poor HLA match (bottom cross-
bar), engraftment of immune competent donor leukocytes in a cy-
toablated recipient is tantamount to lethal GVHD. 
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designate the gene complex coding antigens associated 
with rejection and other kinds of cell-mediated immu-
nity. Bur the evolutionary significance and biologic 
function of the MHC antigens were unknown. 
This changed in 1973-1975 with the discovery by 
Rolf Zinkernagel and Peter Doherty (Nobel laureates, 
1996) of the MHC-restricted mechanisms ofT-cell rec-
ognition of, and response to, non-cytopathic viruses and 
other intracellular microorganisms.143.14G It seemed ob-
vious that the host versus pathogen adaptive immune 
response was the equivalent of primary allograft rejec-
tion. But the seemingly greater complexity of allograft 
rejection, and the inexplicable engraftment of organs in 
the ostensible absence of donor leukocyte chimerism, 
spawned numerous hypotheses to explain the differences 
between the immunology of infection and transplanta-
tion immunology. 
The finding of chimerism in organ recipients has 
eliminated the need for such theories. We have pointed 
out elsewhere that the migration and localization of mo-
bile antigen (ie, microorganisms on one hand, leuko-
cytes on the other) regulate immunologic responsiveness 
or unresponsiveness after both infection and transplan-
tation. l13 Although transplantation is complicated by 
the presence of contemporaneous host-versus-graft and 
graft-versus-host immune reactions and the additional 
factor of therapeutic immunosuppression, the mecha-
nisms and rules of the immune response to pathogens 
and to allografts are basically the same. 123•147 
CONCLUSION 
Bone marrow and organ transplantation are mirror im-
age procedures that induce reciprocally modulating im-
mune reactions: HVG and GVH. The evidence sup-
poning this conclusion has closed the 30-year 
intellectual gap between the two transplant disciplines. 
In so doing, it has been possible to spell out in concrete 
and easily understood terms the meaning and mecha-
nisms of allogeneic tolerance and to clarifY the common-
ality of adaptive immunity to microorganisms and to 
allografts. 
Establishment of this conceptual coherence has de-
pended on knowledge of the historical roots of trans-
plantation, just as linkage of the present with the past is 
essential in all areas of epistemology. The resulting in-
sight into the basis of graft acceptance is the most im-
portant legacy that those of us who are passing from the 
scene have left for those who remain behind. It may 
J Am Coli Surg 
allow the formulation of more rational approaches to 
allotolerance induction or even to strategies for 
xenotransplantation. 148 
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